 <h1>Vfend Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>voriconazole</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about voriconazole. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Vfend.</p><h2>In Summary</h2><p><b>Common side effects of Vfend include:</b> blurred vision, vision color changes, visual disturbance, and enhanced visual perception. <b>Other side effects include:</b> fever, nausea, skin rash, vomiting, and chills.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to voriconazole: oral powder for suspension, oral tablet</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, voriconazole (the active ingredient contained in Vfend) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking voriconazole:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blistering, peeling, loosening of the skin</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficulty seeing at night</li>
<li>fever</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>itching, rash</li>
<li>joint or muscle pain</li>
<li>painful or difficult urination</li>
<li>red irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>trouble breathing</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vision changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blurred vision</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>confusion</li>
<li>dark urine</li>
<li>decreased urine</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>faintness or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>feeling of warmth</li>
<li>increased thirst</li>
<li>irregular or pounding heartbeat</li>
<li>loss of appetite</li>
<li>muscle pain or cramps</li>
<li>muscle spasms or twitching</li>
<li>nausea</li>
<li>nervousness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pounding in the ears</li>
<li>rapid weight gain</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>redness of the face, neck, arms, and occasionally, the upper chest</li>
<li>seizures</li>
<li>stomach pain</li>
<li>slow or fast heartbeat</li>
<li>sweating</li>
<li>trembling</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Agitation</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>hostility or anger</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>irritability</li>
<li>redness or other discoloration of the skin</li>
<li>seeing things that are not there</li>
<li>severe sunburn</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bone pain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of voriconazole may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
<li>headache</li>
<li>vomiting</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to voriconazole: intravenous powder for injection, oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>The most frequently reported side effects in clinical trials were visual disturbances/impairment, fever/pyrexia, nausea, rash, vomiting, diarrhea, chills, headache, increased/abnormal liver function test, peripheral edema, respiratory distress, abdominal pain, tachycardia, and hallucinations.  Side effects that most frequently led to the discontinuation of therapy included visual disturbances, rash, and elevated liver function tests.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Abnormal vision (up to 28.1%), visual disturbances/impairment (including blurred vision, chromatopsia, color vision change, photophobia, chloropsia, color blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, decreased visual acuity, visual brightness, visual field defect, vitreous floaters, xanthopsia)</p>
<p><b>Common</b> (1% to 10%): Photophobia, chromatopsia, retinal hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Papilledema, optic nerve disorder, scleritis, blepharitis, diplopia, oculogyric crisis</p>
<p><b>Rare</b> (0.01% to 0.1%): Optic atrophy, corneal opacity</p>
<p><b>Frequency not reported</b>: Eye hemorrhage, abnormality of accommodation, color blindness, conjunctivitis, eye pain, dry eyes, keratitis, keratoconjunctivitis, mydriasis, night blindness, optic neuritis, retinitis, uveitis, visual field defect, alterations in color perception, decreases in electroretinogram (ERG) waveform amplitude, decreases in the visual field, transient altered perception of light, blurred vision, wavy lines on television or on going to sleep, visual disturbances (included amaurosis [partial/total blindness without visible change in the eye], asthenopia [eye strain], chromatopsia [abnormally colored vision], color blindness, diplopia, photopsia, retinal disorder, blurred vision, decreased visual acuity, visual brightness, visual impairment)</p>
<p><b>Postmarketing reports</b>: Prolonged visual adverse events (including optic neuritis, papilledema)<sup>[Ref]</sup></p><p>Drug-related visual disturbances were common.  In clinical trials, abnormal vision, color vision change, and/or photophobia were reported in about 21% of patients.</p>
<p></p>
<p>In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, color blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters, xanthopsia) were very common with this drug.  These visual impairments were transient and fully reversible; most spontaneously resolved within 1 hour with no clinically significant long-term visual effects.  Attenuation was observed with repeated doses.  The visual impairments were usually mild, rarely resulted in discontinuation of therapy, and were not associated with long-term sequelae.</p>
<p></p>
<p>Visual disturbances/impairments may have been related to higher plasma levels and/or doses.</p>
<p></p>
<p>The mechanism of action of the visual disturbances is unknown; however, the site of action is most likely within the retina.  In a study in healthy subjects examining the effect of this drug on retinal function, this drug caused alterations in color perception, decreases in ERG waveform amplitude, and decreases in the visual field; the ERG changes did not progress over 29 days of therapy.  At 14 days after the last dose, color perception, ERG, and visual fields returned to baseline.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Elevated alkaline phosphatase (up to 22.6%), decreased potassium (up to 16.7%), fever/pyrexia, peripheral edema</p>
<p><b>Common</b> (1% to 10%): Chills, asthenia, face edema (included periorbital edema, lip edema, mouth edema), chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased blood cholesterol, influenza-like illness</p>
<p><b>Frequency not reported</b>: Enlarged abdomen, ascites, cellulitis, edema, flank pain, graft versus host reaction, granuloma, infection, bacterial infection, fungal infection, mucous membrane disorder, multi-organ failure, pain, pelvic pain, sepsis, substernal chest pain, infusion-related side effects (including immediate anaphylactoid-type reactions), mucosal inflammation, hypothermia, lethargy, flushing<sup>[Ref]</sup></p><p>Elevated alkaline phosphatase (greater than 3 times the upper limit of normal [3 x ULN]; up to 22.6%) and decreased potassium (less than 0.9 times the lower limit of normal; up to 16.7%) have been reported.</p>
<p></p>
<p>Infusion-related side effects have included immediate anaphylactoid-type reactions (including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash).<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased blood creatinine (up to 21.4%)</p>
<p><b>Common</b> (1% to 10%): Acute renal failure, abnormal kidney function</p>
<p><b>Uncommon</b> (0.1% to 1%): Nephritis, renal tubular necrosis, increased blood urea</p>
<p><b>Frequency not reported</b>: Increased BUN, decreased CrCl, hydronephrosis, kidney pain, nephrosis, uremia, renal impairment, renal failure<sup>[Ref]</sup></p><p>Increased creatinine (greater than 1.3 x ULN) has been reported in up to 21.4% of patients.</p>
<p></p>
<p>Acute renal failure has been reported in severely ill patients treated with this drug.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated AST (up to 20.3%), elevated total bilirubin (up to 19.4%), elevated ALT (up to 18.9%), abnormal liver function test</p>
<p><b>Common</b> (1% to 10%): Increased hepatic enzymes, cholestatic jaundice, bilirubinemia, jaundice, hepatitis (included drug-induced liver injury, toxic hepatitis, hepatocellular injury, hepatotoxicity)</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic failure, hepatomegaly/enlarged liver, cholecystitis, cholelithiasis</p>
<p><b>Frequency not reported</b>: Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure including fatalities), hepatic coma, elevated GGT/LDH, abnormal ALT, hyperbilirubinemia<sup>[Ref]</sup></p><p>The overall incidence of transaminase increases greater than 3 x ULN (not necessarily comprising a side effect) during clinical studies was 18% in adult patients and 25.8% in pediatric patients treated with this drug.  Increased incidence of abnormal liver function tests may have been related to higher plasma levels and/or doses.  Most abnormal liver function tests resolved during therapy without dose adjustment or resolved after dose adjustment (including therapy discontinuation).</p>
<p></p>
<p>Elevated AST (greater than 3 x ULN; up to 20.3%), total bilirubin (greater than 1.5 x ULN; up to 19.4%), and ALT (greater than 3 x ULN; up to 18.9%) have been reported.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Alopecia, exfoliative dermatitis, maculopapular rash, pruritus, erythema</p>
<p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome, allergic dermatitis, purpura, urticaria, eczema, phototoxicity, photosensitivity reaction, macular rash, papular rash</p>
<p><b>Rare</b> (0.01% to 0.1%): Toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, angioedema, pseudoporphyria, psoriasis, drug eruption</p>
<p><b>Frequency not reported</b>: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), phototoxicity (including bullous erythema, lentigines, keratosis, pseudoporphyria, photoaging), photocarcinogenesis, contact dermatitis, discoid lupus erythematosus, fixed drug eruption, furunculosis, herpes simplex, melanoma, melanosis, skin discoloration, skin disorder, dry skin, squamous cell carcinoma, sweating, blistering eruptions/bullous lesions, worsening of psoriasis, photosensitivity-related skin reactions (e.g., pseudoporphyria, cheilitis, cutaneous lupus erythematosus), generalized rash, pruritic rash, dermatitis, phototoxic reaction</p>
<p><b>Postmarketing reports</b>: Cutaneous lupus erythematosus, ephelides, lentigo, DRESS, actinic keratosis<sup>[Ref]</sup></p><p>Most rashes were of mild to moderate severity.</p>
<p></p>
<p>A photosensitivity reaction (manifested as facial edema and cheilitis) was reported in ambulatory patients (n=5) receiving 200 mg twice daily for chronic invasive Aspergillus 4 weeks after starting therapy.  Symptoms resolved shortly after stopping the drug.  Plasma and serum levels of all-trans retinol and 13-cis retinol were elevated in all the cases (n=3) measured supporting a hypothesis that this drug inhibits a step in the breakdown of all-trans retinoic acid.</p>
<p></p>
<p>A 65-year-old patient experienced pseudoporphyria after minimal sun exposure coincident with use of this drug.  After pseudoporphyria was diagnosed and because the drug could not be stopped, the patient was instructed to avoid the sun and use sunscreens with ultraviolet A and B protection.  The drug was stopped after a year of therapy, but the patient continued to be extremely photosensitive for several months.</p>
<p></p>
<p>A 45-year-old female with a history of non-Hodgkin's lymphoma 3 years post allogeneic bone marrow transplant experienced blistering eruptions coincident with use of this drug.  Her posttransplant course had been complicated by chronic, grade 2, cutaneous graft versus host disease requiring therapy.  The patient had no history of bullous skin lesions.  She was started on 200 mg twice daily as prophylactic antifungal therapy.  One week later, tense blisters were observed on the hips and later on the hands.  There were prodromal burning sensations, but no associated pruritus or pain.  The lesions resolved over 5 to 7 days without scarring.  She experienced recurrent episodes involving her legs and feet.  A biopsy obtained from the knee showed moderate hyperkeratosis, striking atrophy, and extensive basal vacuolization and colloid body formation.  The temporal association of the start of this drug and onset of the eruption raised suspicion that it was the etiologic factor; thus, the drug was discontinued.  The blistering resolved within 2 weeks with no further episodes.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p>
<p><b>Common</b> (1% to 10%): Dizziness, paresthesia, tremor, convulsion, hypertonia (included nuchal rigidity, tetany), somnolence, syncope</p>
<p><b>Uncommon</b> (0.1% to 1%): Ataxia, brain edema, vertigo, hypoesthesia, dysgeusia/altered taste perception/taste perversion, encephalopathy (included hypoxic-ischemic encephalopathy, metabolic encephalopathy), extrapyramidal syndrome/disorder (included akathisia, parkinsonism), peripheral neuropathy, hypoacusis, tinnitus</p>
<p><b>Rare</b> (0.01% to 0.1%): Hepatic encephalopathy, Guillain-Barre syndrome, nystagmus</p>
<p><b>Frequency not reported</b>: Acute brain syndrome, akathisia, amnesia, coma, deafness, dementia, ear pain, encephalitis, grand mal convulsion, intracranial hypertension, neuralgia, neuropathy, otitis externa, taste loss, somnolence during infusion<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain, nausea, vomiting, diarrhea</p>
<p><b>Common</b> (1% to 10%): Cheilitis, dry mouth, gingivitis, dyspepsia, constipation</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, peritonitis, duodenitis, gastroenteritis, glossitis, swollen tongue, pseudomembranous colitis</p>
<p><b>Frequency not reported</b>: Duodenal ulcer perforation, dysphagia, esophageal ulcer, esophagitis, flatulence, gastrointestinal hemorrhage, gum hemorrhage, gum hyperplasia, hematemesis, intestinal perforation, intestinal ulcer, melena, mouth ulceration, parotid gland enlargement, periodontitis, proctitis, rectal disorder, rectal hemorrhage, stomach ulcer, stomatitis, tongue edema, abdominal distention, upper abdominal pain, abdominal tenderness<sup>[Ref]</sup></p><p>There have been postmarketing reports of pancreatitis in pediatric patients.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Respiratory distress (included dyspnea, exertional dyspnea)</p>
<p><b>Common</b> (1% to 10%): Acute respiratory distress syndrome, pulmonary edema, sinusitis</p>
<p><b>Frequency not reported</b>: Increased cough, dyspnea, epistaxis, influenza syndrome, hemoptysis, hypoxia, pharyngitis, pleural effusion, pneumonia, respiratory disorder, respiratory tract infection, rhinitis, voice alteration, upper respiratory tract infection, bronchospasm, nasal congestion, respiratory failure, tachypnea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia, hypoglycemia, hyponatremia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypercholesterolemia, hypomagnesemia</p>
<p><b>Frequency not reported</b>: Decreased glucose tolerance, hypercalcemia, hypercholesterolemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperuricemia, hypocalcemia, hypophosphatemia, anorexia, hyperinsulinemia, hypoalbuminemia, hyperphosphatemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia, hypotension, phlebitis, supraventricular arrhythmia, bradycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Ventricular fibrillation, supraventricular tachycardia, ECG QT prolonged, vasodilatation, ventricular extrasystoles, ventricular tachycardia, thrombophlebitis</p>
<p><b>Rare</b> (0.01% to 0.1%): Torsade de pointes, complete atrioventricular block, bundle branch block, nodal rhythm</p>
<p><b>Frequency not reported</b>: Atrial arrhythmia, atrial fibrillation, bigeminy, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, endocarditis, extrasystoles, heart arrest, hypertension, myocardial infarction, nodal arrhythmia, postural hypotension, pulmonary embolus, supraventricular extrasystoles, palpitation, abnormalities in ECG, ventricular arrhythmia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytopenia (included immune thrombocytopenic purpura), anemia, leukopenia, pancytopenia, agranulocytosis (included febrile neutropenia, neutropenia)</p>
<p><b>Uncommon</b> (0.1% to 1%): Lymphadenopathy, eosinophilia, lymphangitis, bone marrow failure</p>
<p><b>Rare</b> (0.01% to 0.1%): Disseminated intravascular coagulation</p>
<p><b>Frequency not reported</b>: Anemia (macrocytic, megaloblastic, microcytic, normocytic), aplastic anemia, hemolytic anemia, bleeding time increased, cyanosis, ecchymosis, hypervolemia, marrow depression, petechiae, enlarged spleen, thrombotic thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Hallucinations, confusion/confusional state, anxiety, depression, agitation, insomnia</p>
<p><b>Frequency not reported</b>: Abnormal dreams, delirium, depersonalization, euphoria, decreased libido, psychosis, suicidal ideation, musical hallucinations, auditory hallucination, visual hallucination, affect lability<sup>[Ref]</sup></p><p>A 78-year-old man diagnosed with acute myelogenous leukemia experienced musical hallucinations coincident with use of this drug.  The musical hallucinations began acutely and almost immediately after starting therapy (300 mg orally twice daily) for prevention of fungal infection.  After therapy was discontinued, the music became sporadic after 2 days and by the third day the music had ceased.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthritis</p>
<p><b>Frequency not reported</b>: Arthralgia, increased creatine phosphokinase, bone necrosis, bone pain, leg cramps, myalgia, myasthenia, myopathy, osteomalacia, osteoporosis, periostitis deformans</p>
<p><b>Postmarketing reports</b>: Fluorosis, periostitis<sup>[Ref]</sup></p><p>Fluorosis and periostitis have been reported with long-term therapy.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria</p>
<p><b>Uncommon</b> (0.1% to 1%): Proteinuria</p>
<p><b>Frequency not reported</b>: Albuminuria, anuria, blighted ovum, dysmenorrhea, dysuria, epididymitis, glycosuria, hemorrhagic cystitis, impotence, metrorrhagia, oliguria, scrotal edema, urinary incontinence, urinary retention, urinary tract infection, uterine hemorrhage, vaginal hemorrhage<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion site reaction</p>
<p><b>Frequency not reported</b>: Injection site pain, injection site infection/inflammation, catheter site pain<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>During infusion of the IV formulation in healthy subjects, anaphylactoid-type reactions (including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash) have been reported, with symptoms appearing immediately upon starting the infusion.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylactoid reaction</p>
<p><b>Frequency not reported</b>: Allergic reaction, anaphylactoid-type reactions (including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash), drug hypersensitivity<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Adrenal cortex insufficiency/adrenal insufficiency, hypothyroidism</p>
<p><b>Rare</b> (0.01% to 0.1%): Hyperthyroidism</p>
<p><b>Frequency not reported</b>: Diabetes insipidus<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Melanoma and squamous cell carcinoma of the skin have been reported during long-term therapy in patients with photosensitivity skin reactions.  Squamous cell carcinoma has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Melanoma, squamous cell carcinoma of the skin<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Thompson GR 3rd,  Cadena J,  Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v</p><p id="ref_4">4. Sabo JA,  Abdel-Rahman SM "Voriconazole: a new triazole antifungal." Ann Pharmacother 34 (2000): 1032-43</p><p id="ref_5">5. "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY. </p><p id="ref_6">6. Zonios DI,  Gea-Banacloche J,  Childs R,  Bennett JE "Hallucinations during voriconazole therapy." Clin Infect Dis 47 (2008): e7-10</p><p id="ref_7">7. Haylett AK,  Felton S,  Denning DW,  Rhodes LE "Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients." Br J Dermatol 168 (2012): 179-85</p><p id="ref_8">8. Frick MA,  Soler-Palacin P,  Nalda AM,  Guarner ME,  Nadal CF "Photosensitivity in Immunocompromised Patients Receiving Long-term Therapy With Oral Voriconazole." Pediatr Infect Dis J 29 (2010): 480-1</p><p id="ref_9">9. Sambatakou H,  Dupont B,  Lode H,  Denning DW "Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis." Am J Med 119 (2006): 527.e17-24</p><p id="ref_10">10. Boucher HW,  Groll AH,  Chiou CC,  Walsh TJ "Newer systemic antifungal agents : pharmacokinetics, safety and efficacy." Drugs 64 (2004): 1997-2020</p><p id="ref_11">11. Keady S,  Thacker M "Voriconazole in the treatment of invasive fungal infections." Intensive Crit Care Nurs 21 (2005): 370-3</p><p id="ref_12">12. den Hollander JG,  van Arkel C,  Rijnders BJ,  Lugtenburg PJ,  de Marie S,  Levin MD "Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections." J Antimicrob Chemother 57 (2006): 1248-50</p><p id="ref_13">13. Denning DW,  Griffiths CE "Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole." Clin Exp Dermatol 26 (2001): 648-53</p><p id="ref_14">14. Epaulard O,  Leccia MT,  Blanche S, et al. "Phototoxicity and photocarcinogenesis associated with voriconazole." Med Mal Infect 41 (2011): 639-45</p><p id="ref_15">15. Conlon JD,  Dauenhauer M,  Tonkovic-Capin V, et al. "Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients." J Am Acad Dermatol 58 (2008): 484-487</p><p id="ref_16">16. Huang DB,  Wu JJ,  Lahart CJ "Toxic epidermal necrolysis as a complication of treatment with voriconazole." South Med J 97 (2004): 1116-7</p><p id="ref_17">17. Elbaum DJ,  Cowen EW "Voriconazole-associated phototoxic effects and lentigo formation in an african american man." Arch Dermatol 148 (2012): 965-6</p><p id="ref_18">18. Dolan CK,  Hall MA,  Blazes DL,  Norwood CW "Pseudoporphyria as a result of voriconazole use: a case report." Int J Dermatol 43 (2004): 768-71</p><p id="ref_19">19. Pea F,  Viale P "Hallucinations During Voriconazole Therapy: Who Is at Higher Risk and Could Benefit From Therapeutic Drug Monitoring?" Ther Drug Monit  (2008):</p><p id="ref_20">20. Lyoen M,  Rostain F,  Grimault A,  Minello A,  Sgro C "VFEND((R)) (voriconazole)-associated hypoglycaemia without identified drug interaction." Fundam Clin Pharmacol 27 (2013): 570-1</p><p id="ref_21">21. Xu RA,  Lin GY,  Hu LF, et al. "Successful monitoring of voriconazole-associated hyponatremia with therapeutic drug monitoring." Antimicrob Agents Chemother 57 (2013): 2422-3</p><p id="ref_22">22. Boyd AE,  Modi S,  Howard SJ,  Moore CB,  Keevil BG,  Denning DW "Adverse reactions to voriconazole." Clin Infect Dis 39 (2004): 1241-4</p><p id="ref_23">23. Agrawal AK,  Sherman LK "Voriconazole-induced musical hallucinations." Infection 32 (2004): 293-5</p><p id="ref_24">24. Becce F,  Malghem J,  Lecouvet FE,  Berg BC,  Omoumi P "Clinical images: voriconazole-induced periostitis deformans." Arthritis Rheum 64 (2012): 3490</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Vfend (voriconazole)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: azole antifungals</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>VFEND oral/injection</li>
<li>Vfend Oral &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Aspergillosis, Invasive</li>
<li>Blastomycosis</li>
<li>Candidemia</li>
<li>Coccidioidomycosis, Meningitis</li>
<li data-more-config-id="list-data-resources-conditions">... +10 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to voriconazole: intravenous powder for injection, oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>The most frequently reported side effects in clinical trials were visual disturbances/impairment, fever/pyrexia, nausea, rash, vomiting, diarrhea, chills, headache, increased/abnormal liver function test, peripheral edema, respiratory distress, abdominal pain, tachycardia, and hallucinations.  Side effects that most frequently led to the discontinuation of therapy included visual disturbances, rash, and elevated liver function tests.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Abnormal vision (up to 28.1%), visual disturbances/impairment (including blurred vision, chromatopsia, color vision change, photophobia, chloropsia, color blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, decreased visual acuity, visual brightness, visual field defect, vitreous floaters, xanthopsia)</p><p><b>Common</b> (1% to 10%): Photophobia, chromatopsia, retinal hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Papilledema, optic nerve disorder, scleritis, blepharitis, diplopia, oculogyric crisis</p><p><b>Rare</b> (0.01% to 0.1%): Optic atrophy, corneal opacity</p><p><b>Frequency not reported</b>: Eye hemorrhage, abnormality of accommodation, color blindness, conjunctivitis, eye pain, dry eyes, keratitis, keratoconjunctivitis, mydriasis, night blindness, optic neuritis, retinitis, uveitis, visual field defect, alterations in color perception, decreases in electroretinogram (ERG) waveform amplitude, decreases in the visual field, transient altered perception of light, blurred vision, wavy lines on television or on going to sleep, visual disturbances (included amaurosis [partial/total blindness without visible change in the eye], asthenopia [eye strain], chromatopsia [abnormally colored vision], color blindness, diplopia, photopsia, retinal disorder, blurred vision, decreased visual acuity, visual brightness, visual impairment)</p><p><b>Postmarketing reports</b>: Prolonged visual adverse events (including optic neuritis, papilledema)<sup>[Ref]</sup></p><p>Drug-related visual disturbances were common.  In clinical trials, abnormal vision, color vision change, and/or photophobia were reported in about 21% of patients.</p><p></p><p>In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, color blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters, xanthopsia) were very common with this drug.  These visual impairments were transient and fully reversible; most spontaneously resolved within 1 hour with no clinically significant long-term visual effects.  Attenuation was observed with repeated doses.  The visual impairments were usually mild, rarely resulted in discontinuation of therapy, and were not associated with long-term sequelae.</p><p></p><p>Visual disturbances/impairments may have been related to higher plasma levels and/or doses.</p><p></p><p>The mechanism of action of the visual disturbances is unknown; however, the site of action is most likely within the retina.  In a study in healthy subjects examining the effect of this drug on retinal function, this drug caused alterations in color perception, decreases in ERG waveform amplitude, and decreases in the visual field; the ERG changes did not progress over 29 days of therapy.  At 14 days after the last dose, color perception, ERG, and visual fields returned to baseline.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Elevated alkaline phosphatase (up to 22.6%), decreased potassium (up to 16.7%), fever/pyrexia, peripheral edema</p><p><b>Common</b> (1% to 10%): Chills, asthenia, face edema (included periorbital edema, lip edema, mouth edema), chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Increased blood cholesterol, influenza-like illness</p><p><b>Frequency not reported</b>: Enlarged abdomen, ascites, cellulitis, edema, flank pain, graft versus host reaction, granuloma, infection, bacterial infection, fungal infection, mucous membrane disorder, multi-organ failure, pain, pelvic pain, sepsis, substernal chest pain, infusion-related side effects (including immediate anaphylactoid-type reactions), mucosal inflammation, hypothermia, lethargy, flushing<sup>[Ref]</sup></p><p>Elevated alkaline phosphatase (greater than 3 times the upper limit of normal [3 x ULN]; up to 22.6%) and decreased potassium (less than 0.9 times the lower limit of normal; up to 16.7%) have been reported.</p><p></p><p>Infusion-related side effects have included immediate anaphylactoid-type reactions (including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash).<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased blood creatinine (up to 21.4%)</p><p><b>Common</b> (1% to 10%): Acute renal failure, abnormal kidney function</p><p><b>Uncommon</b> (0.1% to 1%): Nephritis, renal tubular necrosis, increased blood urea</p><p><b>Frequency not reported</b>: Increased BUN, decreased CrCl, hydronephrosis, kidney pain, nephrosis, uremia, renal impairment, renal failure<sup>[Ref]</sup></p><p>Increased creatinine (greater than 1.3 x ULN) has been reported in up to 21.4% of patients.</p><p></p><p>Acute renal failure has been reported in severely ill patients treated with this drug.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated AST (up to 20.3%), elevated total bilirubin (up to 19.4%), elevated ALT (up to 18.9%), abnormal liver function test</p><p><b>Common</b> (1% to 10%): Increased hepatic enzymes, cholestatic jaundice, bilirubinemia, jaundice, hepatitis (included drug-induced liver injury, toxic hepatitis, hepatocellular injury, hepatotoxicity)</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic failure, hepatomegaly/enlarged liver, cholecystitis, cholelithiasis</p><p><b>Frequency not reported</b>: Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure including fatalities), hepatic coma, elevated GGT/LDH, abnormal ALT, hyperbilirubinemia<sup>[Ref]</sup></p><p>The overall incidence of transaminase increases greater than 3 x ULN (not necessarily comprising a side effect) during clinical studies was 18% in adult patients and 25.8% in pediatric patients treated with this drug.  Increased incidence of abnormal liver function tests may have been related to higher plasma levels and/or doses.  Most abnormal liver function tests resolved during therapy without dose adjustment or resolved after dose adjustment (including therapy discontinuation).</p><p></p><p>Elevated AST (greater than 3 x ULN; up to 20.3%), total bilirubin (greater than 1.5 x ULN; up to 19.4%), and ALT (greater than 3 x ULN; up to 18.9%) have been reported.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 19%)</p><p><b>Common</b> (1% to 10%): Alopecia, exfoliative dermatitis, maculopapular rash, pruritus, erythema</p><p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome, allergic dermatitis, purpura, urticaria, eczema, phototoxicity, photosensitivity reaction, macular rash, papular rash</p><p><b>Rare</b> (0.01% to 0.1%): Toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, angioedema, pseudoporphyria, psoriasis, drug eruption</p><p><b>Frequency not reported</b>: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), phototoxicity (including bullous erythema, lentigines, keratosis, pseudoporphyria, photoaging), photocarcinogenesis, contact dermatitis, discoid lupus erythematosus, fixed drug eruption, furunculosis, herpes simplex, melanoma, melanosis, skin discoloration, skin disorder, dry skin, squamous cell carcinoma, sweating, blistering eruptions/bullous lesions, worsening of psoriasis, photosensitivity-related skin reactions (e.g., pseudoporphyria, cheilitis, cutaneous lupus erythematosus), generalized rash, pruritic rash, dermatitis, phototoxic reaction</p><p><b>Postmarketing reports</b>: Cutaneous lupus erythematosus, ephelides, lentigo, DRESS, actinic keratosis<sup>[Ref]</sup></p><p>Most rashes were of mild to moderate severity.</p><p></p><p>A photosensitivity reaction (manifested as facial edema and cheilitis) was reported in ambulatory patients (n=5) receiving 200 mg twice daily for chronic invasive Aspergillus 4 weeks after starting therapy.  Symptoms resolved shortly after stopping the drug.  Plasma and serum levels of all-trans retinol and 13-cis retinol were elevated in all the cases (n=3) measured supporting a hypothesis that this drug inhibits a step in the breakdown of all-trans retinoic acid.</p><p></p><p>A 65-year-old patient experienced pseudoporphyria after minimal sun exposure coincident with use of this drug.  After pseudoporphyria was diagnosed and because the drug could not be stopped, the patient was instructed to avoid the sun and use sunscreens with ultraviolet A and B protection.  The drug was stopped after a year of therapy, but the patient continued to be extremely photosensitive for several months.</p><p></p><p>A 45-year-old female with a history of non-Hodgkin's lymphoma 3 years post allogeneic bone marrow transplant experienced blistering eruptions coincident with use of this drug.  Her posttransplant course had been complicated by chronic, grade 2, cutaneous graft versus host disease requiring therapy.  The patient had no history of bullous skin lesions.  She was started on 200 mg twice daily as prophylactic antifungal therapy.  One week later, tense blisters were observed on the hips and later on the hands.  There were prodromal burning sensations, but no associated pruritus or pain.  The lesions resolved over 5 to 7 days without scarring.  She experienced recurrent episodes involving her legs and feet.  A biopsy obtained from the knee showed moderate hyperkeratosis, striking atrophy, and extensive basal vacuolization and colloid body formation.  The temporal association of the start of this drug and onset of the eruption raised suspicion that it was the etiologic factor; thus, the drug was discontinued.  The blistering resolved within 2 weeks with no further episodes.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p><p><b>Common</b> (1% to 10%): Dizziness, paresthesia, tremor, convulsion, hypertonia (included nuchal rigidity, tetany), somnolence, syncope</p><p><b>Uncommon</b> (0.1% to 1%): Ataxia, brain edema, vertigo, hypoesthesia, dysgeusia/altered taste perception/taste perversion, encephalopathy (included hypoxic-ischemic encephalopathy, metabolic encephalopathy), extrapyramidal syndrome/disorder (included akathisia, parkinsonism), peripheral neuropathy, hypoacusis, tinnitus</p><p><b>Rare</b> (0.01% to 0.1%): Hepatic encephalopathy, Guillain-Barre syndrome, nystagmus</p><p><b>Frequency not reported</b>: Acute brain syndrome, akathisia, amnesia, coma, deafness, dementia, ear pain, encephalitis, grand mal convulsion, intracranial hypertension, neuralgia, neuropathy, otitis externa, taste loss, somnolence during infusion<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain, nausea, vomiting, diarrhea</p><p><b>Common</b> (1% to 10%): Cheilitis, dry mouth, gingivitis, dyspepsia, constipation</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, peritonitis, duodenitis, gastroenteritis, glossitis, swollen tongue, pseudomembranous colitis</p><p><b>Frequency not reported</b>: Duodenal ulcer perforation, dysphagia, esophageal ulcer, esophagitis, flatulence, gastrointestinal hemorrhage, gum hemorrhage, gum hyperplasia, hematemesis, intestinal perforation, intestinal ulcer, melena, mouth ulceration, parotid gland enlargement, periodontitis, proctitis, rectal disorder, rectal hemorrhage, stomach ulcer, stomatitis, tongue edema, abdominal distention, upper abdominal pain, abdominal tenderness<sup>[Ref]</sup></p><p>There have been postmarketing reports of pancreatitis in pediatric patients.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Respiratory distress (included dyspnea, exertional dyspnea)</p><p><b>Common</b> (1% to 10%): Acute respiratory distress syndrome, pulmonary edema, sinusitis</p><p><b>Frequency not reported</b>: Increased cough, dyspnea, epistaxis, influenza syndrome, hemoptysis, hypoxia, pharyngitis, pleural effusion, pneumonia, respiratory disorder, respiratory tract infection, rhinitis, voice alteration, upper respiratory tract infection, bronchospasm, nasal congestion, respiratory failure, tachypnea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia, hypoglycemia, hyponatremia</p><p><b>Uncommon</b> (0.1% to 1%): Hypercholesterolemia, hypomagnesemia</p><p><b>Frequency not reported</b>: Decreased glucose tolerance, hypercalcemia, hypercholesterolemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperuricemia, hypocalcemia, hypophosphatemia, anorexia, hyperinsulinemia, hypoalbuminemia, hyperphosphatemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia, hypotension, phlebitis, supraventricular arrhythmia, bradycardia</p><p><b>Uncommon</b> (0.1% to 1%): Ventricular fibrillation, supraventricular tachycardia, ECG QT prolonged, vasodilatation, ventricular extrasystoles, ventricular tachycardia, thrombophlebitis</p><p><b>Rare</b> (0.01% to 0.1%): Torsade de pointes, complete atrioventricular block, bundle branch block, nodal rhythm</p><p><b>Frequency not reported</b>: Atrial arrhythmia, atrial fibrillation, bigeminy, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, endocarditis, extrasystoles, heart arrest, hypertension, myocardial infarction, nodal arrhythmia, postural hypotension, pulmonary embolus, supraventricular extrasystoles, palpitation, abnormalities in ECG, ventricular arrhythmia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytopenia (included immune thrombocytopenic purpura), anemia, leukopenia, pancytopenia, agranulocytosis (included febrile neutropenia, neutropenia)</p><p><b>Uncommon</b> (0.1% to 1%): Lymphadenopathy, eosinophilia, lymphangitis, bone marrow failure</p><p><b>Rare</b> (0.01% to 0.1%): Disseminated intravascular coagulation</p><p><b>Frequency not reported</b>: Anemia (macrocytic, megaloblastic, microcytic, normocytic), aplastic anemia, hemolytic anemia, bleeding time increased, cyanosis, ecchymosis, hypervolemia, marrow depression, petechiae, enlarged spleen, thrombotic thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Hallucinations, confusion/confusional state, anxiety, depression, agitation, insomnia</p><p><b>Frequency not reported</b>: Abnormal dreams, delirium, depersonalization, euphoria, decreased libido, psychosis, suicidal ideation, musical hallucinations, auditory hallucination, visual hallucination, affect lability<sup>[Ref]</sup></p><p>A 78-year-old man diagnosed with acute myelogenous leukemia experienced musical hallucinations coincident with use of this drug.  The musical hallucinations began acutely and almost immediately after starting therapy (300 mg orally twice daily) for prevention of fungal infection.  After therapy was discontinued, the music became sporadic after 2 days and by the third day the music had ceased.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain</p><p><b>Uncommon</b> (0.1% to 1%): Arthritis</p><p><b>Frequency not reported</b>: Arthralgia, increased creatine phosphokinase, bone necrosis, bone pain, leg cramps, myalgia, myasthenia, myopathy, osteomalacia, osteoporosis, periostitis deformans</p><p><b>Postmarketing reports</b>: Fluorosis, periostitis<sup>[Ref]</sup></p><p>Fluorosis and periostitis have been reported with long-term therapy.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Hematuria</p><p><b>Uncommon</b> (0.1% to 1%): Proteinuria</p><p><b>Frequency not reported</b>: Albuminuria, anuria, blighted ovum, dysmenorrhea, dysuria, epididymitis, glycosuria, hemorrhagic cystitis, impotence, metrorrhagia, oliguria, scrotal edema, urinary incontinence, urinary retention, urinary tract infection, uterine hemorrhage, vaginal hemorrhage<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion site reaction</p><p><b>Frequency not reported</b>: Injection site pain, injection site infection/inflammation, catheter site pain<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>During infusion of the IV formulation in healthy subjects, anaphylactoid-type reactions (including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash) have been reported, with symptoms appearing immediately upon starting the infusion.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylactoid reaction</p><p><b>Frequency not reported</b>: Allergic reaction, anaphylactoid-type reactions (including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash), drug hypersensitivity<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Adrenal cortex insufficiency/adrenal insufficiency, hypothyroidism</p><p><b>Rare</b> (0.01% to 0.1%): Hyperthyroidism</p><p><b>Frequency not reported</b>: Diabetes insipidus<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Melanoma and squamous cell carcinoma of the skin have been reported during long-term therapy in patients with photosensitivity skin reactions.  Squamous cell carcinoma has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Melanoma, squamous cell carcinoma of the skin<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Thompson GR 3rd,  Cadena J,  Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v</p><p id="ref_4">4. Sabo JA,  Abdel-Rahman SM "Voriconazole: a new triazole antifungal." Ann Pharmacother 34 (2000): 1032-43</p><p id="ref_5">5. "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY. </p><p id="ref_6">6. Zonios DI,  Gea-Banacloche J,  Childs R,  Bennett JE "Hallucinations during voriconazole therapy." Clin Infect Dis 47 (2008): e7-10</p><p id="ref_7">7. Haylett AK,  Felton S,  Denning DW,  Rhodes LE "Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients." Br J Dermatol 168 (2012): 179-85</p><p id="ref_8">8. Frick MA,  Soler-Palacin P,  Nalda AM,  Guarner ME,  Nadal CF "Photosensitivity in Immunocompromised Patients Receiving Long-term Therapy With Oral Voriconazole." Pediatr Infect Dis J 29 (2010): 480-1</p><p id="ref_9">9. Sambatakou H,  Dupont B,  Lode H,  Denning DW "Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis." Am J Med 119 (2006): 527.e17-24</p><p id="ref_10">10. Boucher HW,  Groll AH,  Chiou CC,  Walsh TJ "Newer systemic antifungal agents : pharmacokinetics, safety and efficacy." Drugs 64 (2004): 1997-2020</p><p id="ref_11">11. Keady S,  Thacker M "Voriconazole in the treatment of invasive fungal infections." Intensive Crit Care Nurs 21 (2005): 370-3</p><p id="ref_12">12. den Hollander JG,  van Arkel C,  Rijnders BJ,  Lugtenburg PJ,  de Marie S,  Levin MD "Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections." J Antimicrob Chemother 57 (2006): 1248-50</p><p id="ref_13">13. Denning DW,  Griffiths CE "Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole." Clin Exp Dermatol 26 (2001): 648-53</p><p id="ref_14">14. Epaulard O,  Leccia MT,  Blanche S, et al. "Phototoxicity and photocarcinogenesis associated with voriconazole." Med Mal Infect 41 (2011): 639-45</p><p id="ref_15">15. Conlon JD,  Dauenhauer M,  Tonkovic-Capin V, et al. "Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients." J Am Acad Dermatol 58 (2008): 484-487</p><p id="ref_16">16. Huang DB,  Wu JJ,  Lahart CJ "Toxic epidermal necrolysis as a complication of treatment with voriconazole." South Med J 97 (2004): 1116-7</p><p id="ref_17">17. Elbaum DJ,  Cowen EW "Voriconazole-associated phototoxic effects and lentigo formation in an african american man." Arch Dermatol 148 (2012): 965-6</p><p id="ref_18">18. Dolan CK,  Hall MA,  Blazes DL,  Norwood CW "Pseudoporphyria as a result of voriconazole use: a case report." Int J Dermatol 43 (2004): 768-71</p><p id="ref_19">19. Pea F,  Viale P "Hallucinations During Voriconazole Therapy: Who Is at Higher Risk and Could Benefit From Therapeutic Drug Monitoring?" Ther Drug Monit  (2008):</p><p id="ref_20">20. Lyoen M,  Rostain F,  Grimault A,  Minello A,  Sgro C "VFEND((R)) (voriconazole)-associated hypoglycaemia without identified drug interaction." Fundam Clin Pharmacol 27 (2013): 570-1</p><p id="ref_21">21. Xu RA,  Lin GY,  Hu LF, et al. "Successful monitoring of voriconazole-associated hyponatremia with therapeutic drug monitoring." Antimicrob Agents Chemother 57 (2013): 2422-3</p><p id="ref_22">22. Boyd AE,  Modi S,  Howard SJ,  Moore CB,  Keevil BG,  Denning DW "Adverse reactions to voriconazole." Clin Infect Dis 39 (2004): 1241-4</p><p id="ref_23">23. Agrawal AK,  Sherman LK "Voriconazole-induced musical hallucinations." Infection 32 (2004): 293-5</p><p id="ref_24">24. Becce F,  Malghem J,  Lecouvet FE,  Berg BC,  Omoumi P "Clinical images: voriconazole-induced periostitis deformans." Arthritis Rheum 64 (2012): 3490</p><h2>More about Vfend (voriconazole)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: azole antifungals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>VFEND oral/injection</li>
<li>Vfend Oral &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Aspergillosis, Invasive</li>
<li>Blastomycosis</li>
<li>Candidemia</li>
<li>Coccidioidomycosis, Meningitis</li>
<li data-more-config-id="list-data-resources-conditions">... +10 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>